X
AbbVie makes case for Humira follow-on upadacitinib at EULAR
https://pharmaphorum.com/news/abbvie-makes-case-for-humira-follow-on-upadacitinib-at-eular/
Rheumatoid arthritis
Biosimilars underused in rheumatoid arthritis on the NHS – experts
Experts call for lower disease activity threshold for biologic drugs
Celltrion hopes to outdo inflammatory disease rivals with SC infliximab
Drugmaker could file in EU in coming weeks, according to report
More good news for AbbVie in rheumatoid arthritis
AbbVie has reported positive top-line results for its oral JAK1-selective inhibitor in rheumatoid arthritis (RA), bringing it closer to a potential new early treatment option for patients.
